media coverage 2015... · 14 september 2015 dementia consortium funds project focusing on als and...
TRANSCRIPT
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 1 of 21
Announcement
14 September 2015
Dementia Consortium funds project focusing on ALS and FTLD
Table of coverage Date Publication/Website Title
15/09/2015 Pharma Times Dementia Consortium funds protein clumps project
16/09/2015 Drug Target Review Dementia Consortium funds project focusing on ALS and
FTLD
18/09/2015 Technology Networks Dementia Consortium Funds Project Focusing on ALS and
FTLD
14/09/2015 Facebook Dementia Consortium Funds Project Focusing on ALS and
FTLD
14/09/2015 Linkedin Dementia Consortium Funds Project Focusing on ALS and
FTLD
14/09/2015 One Nucleus Dementia Consortium funds project focusing on ALS and
FTLD
14/09/2015 Select Science Dementia Consortium Funds Project Focusing on ALS and
FTLD
14/09/2015 Twitter Dementia Consortium funds project focusing on ALS and
FTLD
14/09/2015 World News.com Dementia Consortium MRCT, Cambridge funds ICGEB
project on ALS and FTLD
15/09/2015 Noodls Dementia Consortium MRCT, Cambridge funds ICGEB
project on ALS and FTLD
15/09/2015 Right Relevance Dementia Consortium funds protein clumps project
17/09/2015 Life Sciences Index Dementia Consortium Funds Project Focusing on ALS and
FTLD
21/09/2015 The Italian Insider Italian team unites with British company to find cure for
dementia
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 2 of 21
Date Publication/Website Title
15/09/2015 Pharma Times Dementia Consortium funds protein clumps project
Dementia Consortium funds protein clumps project
The Dementia Consortium is streaming £305,000 into a project aiming to discover new therapeutics for Amyotrophic Lateral Sclerosis and Frontotemporal Lobar degeneration, the most common cause of dementia in people aged under 50. Both conditions are characterised by the build-up of protein clumps, which can disrupt vital nerve cell communication and eventually cause nerve cell death. The project aims to identify new agents able to clear the misfolded protein TDP-43, which has shown promise as a target in early research, potentially forming the basis of future drug development programmes. With cash from the Dementia Consortium, a unique charity-private £3-million partnership between Alzheimer’s Research UK, MRC Technology and the pharmas Eisai and Lilly, researchers at non-profit group the International Centre for Genetic Engineering and Biotechnology in Trieste will develop assays and perform high-content screening to test libraries of potential compounds for their ability to clear clumps of TDP-43. In partnership with MRC Technology, the researchers will then test promising drugs in cells and animals, to understand how they work and explore whether they can improve symptoms of ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD. “Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function,” said Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, noting that the funding “will allow us to progress our research in collaboration with MRC Technology to the next stage”.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 3 of 21
Date Publication/Website Title
14/09/2015 Select Science Dementia Consortium Funds Project Focusing on ALS and
FTLD
Dementia Consortium Funds Project Focusing on ALS and FTLD
Project will identify new potential therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD)
The Dementia Consortium has awarded £305,000 of funding to a project identifying new
therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD).
A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste,
Italy will join forces with London-based MRC Technology to take on the project, with funding
provided by Alzheimer’s Research UK.
While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the
most common cause of dementia in people under the age of 50, experience different symptoms,
both diseases are associated with the same biological processes. Both are characterized by the build-
up of ‘protein clumps’ – aggregates of misfolded versions of a protein called TAR DNA-binding
protein 43 (TDP-43). This build-up can disrupt vital nerve cell communication and eventually cause
nerve cell death. Sadly, no treatments exist to halt the spread of damage in these diseases. MRC
Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have
set out to tackle this lack of treatments and aim to identify agents capable of clearing misfolded
proteins, which could form the basis of future much-needed drug development programs.
Using new investment from the Dementia Consortium, a unique charity-private partnership between
Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly,
researchers at ICGEB will develop assays and perform high-content screening to test libraries of
potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting expertise
across the continent, the two research teams will work in partnership to test promising drugs in cells
and animals, to understand how they work and explore whether they can improve symptoms of ALS
and FTLD.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 4 of 21
Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented: “Our
initial research into TDP-43 has showed promising results, with some compounds able to enhance
aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us
to progress our research in collaboration with MRC Technology to the next stage.”
Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: “Combining the experience of
ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug discovery and
translation, means we can progress promising science from academia towards effective new
treatments for patients.”
Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form of
dementia, but one that disproportionately impacts people under 65. Typical symptoms include
behavioral and personality changes, as well as a lack of social awareness. Managing these symptoms
can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell
damage in the brain. By combining expertise through the Dementia Consortium, we hope to
accelerate progress from academic laboratories across the world into much sought-after treatments
in the clinic.”
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 5 of 21
Date Publication/Website Title
18/09/2015 Technology Networks Dementia Consortium Funds Project Focusing on ALS and
FTLD
Dementia Consortium Funds Project Focusing on ALS and FTLD Project will identify new potential therapeutics for Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
The Dementia Consortium has awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD). A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with funding provided by Alzheimer’s Research UK. While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the most common cause of dementia in people under the age of 50, experience different symptoms, both diseases are associated with the same biological processes. Both are characterized by the build-up of ‘protein clumps’ - aggregates of misfolded versions of a protein called TAR DNA-binding protein 43 (TDP-43). This build-up can disrupt vital nerve cell communication and eventually cause nerve cell death. Sadly, no treatments exist to halt the spread of damage in these diseases. MRC Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to tackle this lack of treatments and aim to identify agents capable of clearing misfolded proteins, which could form the basis of future much-needed drug development programmes. Using new investment from the Dementia Consortium, a unique charity-private partnership between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly, researchers at ICGEB will develop assays and perform high-content screening to test libraries of potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting expertise across the continent, the two research teams will work in partnership to test promising drugs in cells and animals, to understand how they work and explore whether they can improve symptoms of ALS and FTLD. Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented: “Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us to progress our research in collaboration with MRC Technology to the next stage.”
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 6 of 21
Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: “Combining the experience of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug discovery and translation, means we can progress promising science from academia towards effective new treatments for patients.” Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form of dementia, but one that disproportionately impacts people under 65. Typical symptoms include behavioural and personality changes, as well as a lack of social awareness. Managing these symptoms can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we hope to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic.” The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. By uniting expertise, this focused cash injection will bridge the gap between academic research and the pharmaceutical industry in the search for new drugs to slow the development of neurodegenerative diseases that cause dementia. The Dementia Consortium is open to global research teams with innovative targets that need accelerating through the drug discovery process.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 7 of 21
Date Publication/Website Title
14/09/2015 One Nucleus Dementia Consortium funds project focusing on ALS
and FTLD
Dementia Consortium funds project focusing on ALS
and FTLD
London, UK, 14 September 2015: The Dementia Consortium has awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD). A team at the International Centre for Genetic Engineering and
Biotechnology (ICGEB) in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with funding provided by Alzheimer’s Research UK. While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the most common cause of dementia in people under the age of 50, experience different symptoms, both diseases are associated with the same biological processes. Both are
characterised by the build-up of ‘protein clumps’ – aggregates of misfolded versions of a protein
called TAR DNA-binding protein 43 (TDP-43). This build-up can disrupt vital nerve cell communication and eventually cause nerve cell death. Sadly, no treatments exist to halt the spread of damage in these diseases. MRC Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to tackle this lack of treatments and aim to identify agents capable of clearing misfolded proteins, which could form the basis of future much-needed drug development programmes.
Using new investment from the Dementia Consortium, a unique charity-private partnership between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly, researchers at ICGEB will develop assays and perform high-content screening to test libraries of potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting expertise across the continent, the two research teams will work in partnership to test promising drugs in cells and animals, to understand how they work and explore whether they can improve symptoms
of ALS and FTLD.
Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented: “Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us to progress our research in collaboration with MRC Technology to the next stage.”
Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: “Combining the experience of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug discovery and translation, means we can progress promising science from academia towards effective new treatments for patients.” Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form of dementia, but one that disproportionately impacts people under 65. Typical symptoms include
behavioural and personality changes, as well as a lack of social awareness. Managing these
symptoms can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 8 of 21
hope to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic.” The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. By uniting expertise, this focused cash injection will bridge the gap between academic research and the
pharmaceutical industry in the search for new drugs to slow the development of neurodegenerative diseases that cause dementia. The Dementia Consortium is open to global research teams with innovative targets that need accelerating through the drug discovery process. For further information please visit http://www.dementiaconsortium.org/.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 9 of 21
Date Publication/Website Title
16/09/2015 Drug Target Review Dementia Consortium funds project focusing on ALS and
FTLD
Dementia Consortium funds project focusing on
ALS and FTLD
The Dementia Consortium has awarded £305,000 of funding to a project
identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS)
and Frontotemporal Lobar degeneration (FTLD).
A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste
will join forces with MRC Technology to take on the project, with funding provided by Alzheimer’s
Research UK.
While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD
experience different symptoms, both diseases are associated with the same biological processes. Both
are characterised by the build-up of ‘protein clumps’ – aggregates of misfolded versions of a protein
called TAR DNA-binding protein 43 (TDP-43). This build-up can disrupt vital nerve cell
communication and eventually cause nerve cell death. Sadly, no treatments exist to halt the spread of
damage in these diseases. MRC Technology and ICGEB have set out to identify agents capable of
clearing misfolded proteins, which could form the basis of future much-needed drug development
programmes.
Initial research into TDP-43 showed promising results
Using new investment from the Dementia Consortium, a unique £3m drug discovery collaboration
between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and
Lilly, researchers at ICGEB will develop assays and perform high-content screening to test libraries of
potential compounds for their ability to clear clumps of misfolded TDP-43. The two research teams
will work in partnership to test promising drugs in cells and animals, to understand how they work
and explore whether they can improve symptoms of ALS and FTLD.
Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented, “Our
initial research into TDP-43 has showed promising results, with some compounds able to enhance
aggregate clearance by more than 50% and fully restore TDP 43 function.”
Dr Justin Bryans, Director of Drug Discovery at MRC Technology, said, “Combining the experience
of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug
discovery and translation, means we can progress promising science from academia towards effective
new treatments for patients.”
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 10 of 21
Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added, “FTLD is a rare form of
dementia, but one that disproportionately impacts people under 65. Typical symptoms include
behavioural and personality changes, as well as a lack of social awareness. Managing these symptoms
can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell
damage in the brain. By combining expertise through the Dementia Consortium, we hope to
accelerate progress from academic laboratories across the world into much sought-after treatments in
the clinic.”
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 11 of 21
Date Publication/Website Title
17/09/2015 Life Sciences Index Dementia Consortium Funds Project Focusing on ALS and
FTLD
Dementia Consortium Funds Project Focusing on ALS and
FTLD
The Dementia Consortium has awarded £305,000 of funding to a project identifying new
therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration
(FTLD). A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB)
in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with
funding provided by Alzheimer’s Research UK.
Although people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and
FTLD, the most common cause of dementia in people under the age of 50, experience different
symptoms, both diseases are associated with the same biological processes. Both are
characterized by the build-up of ‘protein clumps’ – aggregates of misfolded versions of a protein
called TAR DNA-binding protein 43 (TDP-43).
This build-up can disrupt vital nerve cell communication and eventually cause nerve cell death.
Sadly, no treatments exist to halt the spread of damage in these diseases. MRC Technology and
the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to
tackle this lack of treatments and aim to identify agents capable of clearing misfolded proteins,
which could form the basis of future much-needed drug development programmes.
Using new investment from the Dementia Consortium, a unique charity-private partnership
between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai
and Lilly, researchers at ICGEB will develop assays and perform high-content screening to test
libraries of potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting
expertise across the continent, the two research teams will work in partnership to test promising
drugs in cells and animals, to understand how they work and explore whether they can improve
symptoms of ALS and FTLD.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 12 of 21
Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB,
commented: “Our initial research into TDP-43 has showed promising results, with some
compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43
function. This funding will allow us to progress our research in collaboration with MRC
Technology to the next stage.”
Dr Justin Bryans, Director of Drug Discovery at MRC Technology, said: “Combining the
experience of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise
in drug discovery and translation, means we can progress promising science from academia
towards effective new treatments for patients.”
Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form
of dementia, but one that disproportionately impacts people under 65. Typical symptoms include
behavioural and personality changes, as well as a lack of social awareness. Managing these
symptoms can be incredibly challenging and we’ve gone too long without a therapy that can halt
nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we
hope to accelerate progress from academic laboratories across the world into much sought-after
treatments in the clinic.”
The Dementia Consortium is a unique £3 million drug discovery collaboration between
Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly.
By uniting expertise, this focused cash injection will bridge the gap between academic research
and the pharmaceutical industry in the search for new drugs to slow the development of
neurodegenerative diseases that cause dementia.
The Dementia Consortium is open to global research teams with innovative targets that need
accelerating through the drug discovery process. For further information please
visit http://www.dementiaconsortium.org/.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 13 of 21
Date Publication/Website Title
15/09/2015 Noodls Dementia Consortium MRCT, Cambridge funds ICGEB
project on ALS and FTLD
Dementia Consortium MRCT, Cambridge funds ICGEB
project on ALS and FTLD
ALS (also known as motor neurone disease or Lou Gehrig's Disease) and FTLD are characterised by the formation of cytoplasmic inclusions of misfolded TAR DNA-binding protein 43 (TDP-43) which affect the function of neurons. MRC Technology (London, UK) and the International Centre
for Genetic Engineering and Biotechnology (ICGEB, Trieste, Italy) aim to identify agents capable of clearing misfolded proteins, which could form the basis of future drug development programmes.
Researchers at ICGEB have developed a novel assay system to test potential drug candidates for
their ability to clear aggregated TDP-43 and will now investigate new active agents and characterise their mechanism of action. MRC Technology will develop cellular assays and carry out High Content Screening using its compound libraries, and hits will be confirmed by ICGEB in both in vitro and in vivo behavioural models.
Marco Baralle, Group Leader, Biotechnology Development, ICGEB, commented: "Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us to progress our research in collaboration with MRC Technology to the next stage."
Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: "Combining the experience of ICGEB and Alzheimer's Research UK, and MRC Technology's expertise in drug discovery and translation, means we can progress promising science from academia into effective new
treatments for patients."
Dr Eric Karran, Director of Research at Alzheimer's Research UK, added: "FTLD is a rare form of dementia, but one that disproportionately impacts people under 65. Typical symptoms include behavioural and personality changes, as well as a lack of social awareness. Managing these symptoms can be incredibly challenging and we've gone too long without a therapy that can halt nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we
hope to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic."
The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer's Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly which aims tol bridge the gap between academic research and the pharmaceutical industry in the search for new drugs to slow the development of neurodegenerative diseases that cause dementia.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 14 of 21
Date Publication/Website Title
21/09/2015 The Italian Insider Italian team unites with British company to find
cure for dementia
Italian team unites with British company to find cure for dementia
International Centre for Genetic Engineering and Biotechnology in Trieste joins fight to cure dementia
LONDON — The Dementia Consortium awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD) on September 14. A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with funding provided by Alzheimer’s Research UK. Whilst people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the most common cause of dementia in people under the age of 50, experience different symptoms, both diseases are associated with the same biological processes. Both consist of the accumulation of “protein clumps”, which can disrupt vital nerve cell communication, and can eventually lead to nerve cell death. Unfortunately, at the current moment in time, no treatments exist to halt the spread of damage in these diseases. MRC Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to tackle this lack of treatments. The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. Alzheimer’s Research UK is the UK’s leading charity specialising in seeking preventions, treatments, and ultimately a cure for dementia. It is currently supporting dementia-related research projects that are worth over £26 million in some of the top universities in the United Kingdom.
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 15 of 21
Date Publication/Website Title
15/09/2015 Right Relevance Dementia Consortium funds protein clumps project
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 16 of 21
,
Date Publication/Website Title
14/09/2015 World News.com Dementia Consortium MRCT, Cambridge funds
ICGEB project on ALS and FTLD
Dementia Consortium MRCT, Cambridge funds
ICGEB project on ALS and FTLD ALS (also known as motor neurone disease or Lou Gehrig's Disease) and FTLD are characterised by the formation of cytoplasmic inclusions of
misfolded TAR...
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 17 of 21
Date Publication/Website Title
14/09/2015 Facebook Dementia Consortium Funds Project Focusing on ALS
and FTLD
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 18 of 21
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 19 of 21
Date Publication/Website Title
14/09/2015 Linkedin Dementia Consortium Funds Project Focusing on ALS and
FTLD
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 20 of 21
Date Publication/Website Title
14/09/2015 Twitter Dementia Consortium funds project focusing on ALS and
FTLD
Media Coverage
Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:
[email protected] Page 21 of 21